alexa The Effect of EGFR Inhibitor Treatment in KRAS G13D Mutated Metastatic Colorectal Cancer Background | OMICS International| Abstract
ISSN: 2471-2671

Archives of Surgical Oncology
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
  • Mini Review   
  • Arch Surg Oncol 2017, Vol 3(2): 2
  • DOI: 10.4172/2471-2671.1000122

The Effect of EGFR Inhibitor Treatment in KRAS G13D Mutated Metastatic Colorectal Cancer Background

Thavaneswaran S1*, Shapiro J2 and Segelov E3
1Department of Medical Oncology, The Kinghorn Cancer Centre and Garvan Institute of Medical Research, , Australia
2Department of Medical Oncology, Cabrini Hospital, , Melbourne, VIC, Australia
3Department of Medical Oncology, Monash Health and Monash University, , Australia
*Corresponding Author : Thavaneswaran S, Department of Medical Oncology, The Kinghorn Cancer Centre and Garvan Institute of Medical Research, Australia, Tel: +61 293555655, Email: [email protected]

Received Date: Mar 23, 2017 / Accepted Date: Apr 05, 2017 / Published Date: Apr 12, 2017

Abstract

Cetuximab and panitumumab are monoclonal antibodies directed against the Epidermal Growth Factor Receptor (EGFR) which are now standard treatments for RAS Wild Type (WT) metastatic Colorectal Cancer (CRC), with efficacy in all lines of therapy. The evolution of the use of the EGFR-Inhibitors (EGFR-I) is the landmark journey of the application of a predictive marker and its translation into clinical utility. Here we describe how the evaluation of EGFR-I in patients with the resistant biomarker, i.e., RAS mutant, led to clinical suspicion that the G13D subset of mutated tumours may in fact be an exception. The hypothesis, raised from preclinical data, then retrospective analysis of trial outcomes, was subsequently prospectively tested by our group in a randomised clinical trial (RCT; the ICECREAM study) which unfortunately did not reveal that this particular mutation conferred sensitivity to EGFRI. The investigation of EGFR-I in KRAS G13D mutated metastatic CRC is a good example of the ability of international collaboration to perform RCTs even in rare molecular subtypes, as well as confirming the role of prospective clinical trial evaluation of hypotheses raised by unplanned subgroup analyses.

Keywords: Monoclonal antibodies; Epidermal growth factor receptor; Cetuximab; Colorectal cancer

Citation: Thavaneswaran S, Shapiro J, Segelov E (2017) The Effect of EGFR Inhibitor Treatment in KRAS G13D Mutated Metastatic Colorectal Cancer Background. Arch Surg Oncol 3: 122. Doi: 10.4172/2471-2671.1000122

Copyright: © 2017 Thavaneswaran S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Select your language of interest to view the total content in your interested language

Post Your Comment Citation
Share This Article
Article Usage
  • Total views: 1540
  • [From(publication date): 0-2017 - Nov 21, 2019]
  • Breakdown by view type
  • HTML page views: 1468
  • PDF downloads: 72
Top